Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Pharmacokinetics of HU6 Tablet and Capsule in Obese Subjects
NCT05433506Phase 1Completed
- Sponsor
- Rivus Pharmaceuticals, Inc.
- Start
- Sep 2022
- Primary completion
- Jan 2023
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of HU6 in obesity (3 arms), sponsored by Rivus Pharmaceuticals, Inc. Primary endpoint: Maximum Plasma Concentration at 150 days. Started Sep 2022; status: completed.
02
Drugs
HU6
03
Conditions
obesity
Beyond the preview
Go deeper on NCT05433506.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05433506.